The pathophysiology of hypertension in systemic lupus erythematosus

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 296, Issue 4, 2009, Pages

  Ryan, Michael J ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Inflammation; Renal

Indexed keywords

CYTOKINE; ENDOTHELIN; ESTROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEX HORMONE;

ENDOCRINE SYSTEM; HUMAN; HYPERTENSION; KIDNEY; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCRINE SYSTEM; ENDOTHELIUM, VASCULAR; ESTROGENS; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; OXIDATIVE STRESS; RISK FACTORS;

EID: 65949112477     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.90864.2008     Document Type: Review

References (148)

1. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 36: 1111-1120, 1993. (Pubitemid 23229288)
2. Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30: 493-496, 2003. (Pubitemid 36301940)
3. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 280: R1388-R1392, 2001.
4. Alves JD, Ames PR. Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome. Immunobiology 207: 23-28, 2003.
5. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 5: 383-390, 2003.
6. Anonymous. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 42: 1785-1796, 1999.
7. Anonymous. Health, United States, 2007, With Chartbook on Trends in Health of Americans. Hyattsville, MD: Natl Center Health Stat, 2007.
8. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor-α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50: 3161-3169, 2004. (Pubitemid 39371992)
9. Askanase AD, Buyon JP. Reproductive health in SLE. Best Pract Res Clin Rheumatol 16: 265-280, 2002. (Pubitemid 36526643)
10. Bae SC, Kim SJ, Sung MK. Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatol Int 22: 238-243, 2002.
11. Bagi Z, Hamar P, Kardos M, Koller A. Lack of flow-mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice. Lupus 15: 326-334, 2006. (Pubitemid 44032707)
12. A receptors for endothelin regulation. Biochem Biophys Res Commun 238: 861-865, 1997.
13. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens 19: 149-154, 2005. (Pubitemid 40220638)
14. lpr mice. J Lipid Res 47: 2382-2391, 2006.
15. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med 61: 273-277, 2003. (Pubitemid 39089423)
16. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108: 2993-2999, 2003. (Pubitemid 37553568)
17. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 12: 1623-1635, 2006.
18. Borst SE. The role of TNF-α in insulin resistance. Endocrine 23: 177-182, 2004. (Pubitemid 39140231)
19. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 143: 3470-3475, 1989.
20. Bruce IN. Atherogenesis and autoimmune disease: the model of lupus. Lupus 14: 687-690, 2005.
21. Budman DR, Steinberg AD. Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med 136: 1003-1007, 1976.
22. Burnett R, Ravel G, Descotes J. Clinical and histopathological progression of lesions in lupus-prone (NZB x NZW)F1 mice. Exp Toxicol Pathol 56: 37-44, 2004. (Pubitemid 39486844)
23. Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-α deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun 9: 137-152, 2008.
24. Carlsoo B, Ostberg Y. Ultrastructural observations on the parotitis autoimmunica in the NZB/NZW hybrid mice. Acta Otolaryngol 85: 298-306, 1978. (Pubitemid 8284590)
25. Casellas AM, Prat A, Llera A, Manni J, Boveris A, Sarano JF. Increased superoxide production by polymorphonuclear leukocytes in systemic lupus erythematosus. Clin Exp Rheumatol 9: 511-514, 1991.
26. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest 93: 17-25, 1994. (Pubitemid 24983180)
27. Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep 2: 39-43, 2000.
28. Clavell AL, Stingo AJ, Margulies KB, Brandt RR, Burnett JC Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol Renal Fluid Electrolyte Physiol 268: F455-F460, 1995.
29. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 305: 67-88, 2006. (Pubitemid 47400265)
30. Coleman TG, Guyton AC, Young DB, DeClue JW, Norman RA, Manning J, Manning RD Jr. The role of the kidney in essential hypertension. Clin Exp Pharmacol Physiol 2: 571-581, 1975.
31. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51: 1583-1589, 1997. (Pubitemid 27239915)
32. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to antitumor necrosis factor-α agents. Semin Arthritis Rheum 37: 381-387, 2008.
33. Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS. Inflammatory modulation of PPAR-γ expression and activity. Clin Immunol 118: 276-283, 2006. (Pubitemid 43199667)
34. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 48: 255-261, 1999.
35. Cuzzocrea S, Mazzon E, Dugo L, Di PR, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. FASEB J 18: 94-101, 2004.
36. Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF, Berland Y. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int 60: 2215-2221, 2001. (Pubitemid 33070464)
37. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFα, p55 srTNFα, p75srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18: 17-22, 1999. (Pubitemid 29104747)
38. De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP, Singh RR. An ACE inhibitor reduces Th2 cytokines and TGF-β1 and TGF-β2 isoforms in murine lupus nephritis. Kidney Int 65: 846-859, 2004. (Pubitemid 38251060)
39. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59: 243-251, 2000. (Pubitemid 30305564)
40. Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 67: 1211-1241, 2007. (Pubitemid 46880983)
41. 2 genotype and risk of systemic lupus erythematosus in Koreans. Lupus 14: 351-355, 2005.
42. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 278-301, 2003. (Pubitemid 36724371)
43. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 94: 585-591, 1994. (Pubitemid 24250987)
44. Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC, Cardona-Munoz EG, Salazar-Paramo M, Gonzalez-Ortiz M, Martinez- Abundis E, Gamez-Nava JI. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int 22: 138-141, 2002.
45. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280, 2006.
46. Gehi A, Webb A, Nolte M, Davis J Jr. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum 48: 1067-1070, 2003. (Pubitemid 36418249)
47. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 15: 148-155, 2006.
48. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. Hypertension 48: 473-481, 2006. (Pubitemid 44253743)
49. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60: 14-30, 2001. (Pubitemid 32587535)
50. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52: 584-594, 1972.
51. Guyton AC, Manning RD Jr, Hall JE, Norman RA Jr, Young DB, Pan YJ. The pathogenic role of the kidney. J Cardiovasc Pharmacol 6 Suppl 1: S151-S161, 1984.
52. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 33: 605-618, 2000.
53. Hang LM, Izui S, Dixon FJ. (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 154: 216-221, 1981.
54. Herlitz H, Edeno C, Mulec H, Westberg G, Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron 38: 253-256, 1984. (Pubitemid 15200061)
55. Herlitz H, Tarkowski A, Svalander C, Volkmann R, Westberg G. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice. Int Arch Allergy Appl Immunol 85: 272-277, 1988. (Pubitemid 18080574)
56. Hogarth MB, Slingsby JH, Allen PJ, Thompson EM, Chandler P, Davies KA, Simpson E, Morley BJ, Walport MJ. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol 161: 2753-2761, 1998. (Pubitemid 28425694)
57. phox message expressions in primary endothelial cells. Metabolism 50: 3-11, 2001.
58. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune "lupus" nephritis. Nature 331: 356-358, 1988.
59. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator- activated receptor-γ (PPARγ) in Alzheimer's disease: therapeutic implications. CNS Drugs 22: 1-14, 2008. (Pubitemid 350243363)
60. Johnson SR, Harvey PJ, Floras JS, Iwanochko M, Ibanez D, Gladman DD, Urowitz M. Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 13: 590-593, 2004. (Pubitemid 39145488)
61. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 50: 526-527, 1991.
62. phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109: 1795-1801, 2004.
63. Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, Ikeda U, Nishiuma S, Matsuo M, Shimada K. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol 32: 444-450, 1998. (Pubitemid 28397740)
64. Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, Baird T, Hutchings D, Bruner G, Scofield RH, Moser K, Harley JB. Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol Cell Endocrinol 177: 81-85, 2001. (Pubitemid 32506808)
65. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol 19: 57-66, 1999.
66. Kiberd BA. Murine lupus nephritis. A structure-function study. Lab Invest 65: 51-60, 1991.
67. Kipen Y, Briganti EM, Strauss BJ, Littlejohn GO, Morand EF. Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology (Oxf) 38: 59-65, 1999. (Pubitemid 29509658)
68. Kipen Y, Strauss BJ, Morand EF. Body composition in systemic lupus erythematosus. Br J Rheumatol 37: 514-519, 1998. (Pubitemid 28371851)
69. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 30: 2038-2047, 2000. (Pubitemid 30456200)
70. phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511-515, 2002.
71. Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am J Hypertens 17: 852-860, 2004. (Pubitemid 39201104)
72. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 18-27, 2003. (Pubitemid 36565032)
73. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935-H940, 2006.
74. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a meta-analysis. J Rheumatol 33: 698-702, 2006.
75. Leibovitz E, Schiffrin EL. PPAR activation: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 50: 120-125, 2007. (Pubitemid 47267737)
76. Lemoine R, Berney T, Shibata T, Fulpius T, Gyotoku Y, Shimada H, Sawada S, Izui S. Induction of "wire-loop" lesions by murine monoclonal IgG3 cryoglobulins. Kidney Int 41: 65-72, 1992.
77. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52: 256-263, 2008.
78. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29: 292-297, 2002.
79. Lord G. Role of leptin in immunology. Nutr Rev 60: S35-S38, 2002.
80. Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice: studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106: 243-252, 1996. (Pubitemid 26359889)
81. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 17: 126-141, 1987.
82. Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 25: 311-317, 2005. (Pubitemid 41160989)
83. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415, 1997. (Pubitemid 27084212)
84. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin- 1 gene by TNF-α. Am J Physiol Cell Physiol 262: C854-C861, 1992.
85. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 48: 149-156, 2006. (Pubitemid 44297537)
86. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 70: 863-870, 1994.
87. McMurray RW, Hoffman RW, Nelson W, Walker SE. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus - analyses of strain, gender, and age effects. Clin Immunol Immunopathol 84: 260-268, 1997. (Pubitemid 27398025)
88. Metsarinne KP, Nordstrom DC, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 12: 93-96, 1992.
89. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003. (Pubitemid 37169339)
90. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61: 391-415, 1999. (Pubitemid 29143176)
91. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Renal Physiol Biochem 16: 233-243, 1993. (Pubitemid 23256561)
92. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489, 1995.
93. Nakano M, Ueno M, Hasegawa H, Watanabe T, Kuroda T, Ito S, Arakawa M. Renal haemodynamic characteristics in patients with lupus nephritis. Ann Rheum Dis 57: 226-230, 1998. (Pubitemid 28323264)
94. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38: 1008-1017, 2003. (Pubitemid 37221684)
95. Oates JC, Reilly CM, Crosby MB, Gilkeson GS. Peroxisome proliferator- activated receptor γ agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum 46: 598-605, 2002.
96. Parsa A, Peden E, Lum RF, Seligman VA, Olson JL, Li H, Seldin MF, Criswell LA. Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families. Genes Immun 3 Suppl 1: S42-S46, 2002.
97. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437: 759-763, 2005. (Pubitemid 41486547)
98. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 175: 1415-1423, 2005. (Pubitemid 41023040)
99. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 101: 123-143, 2005. (Pubitemid 41368071)
100. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9: 170-175, 2000. (Pubitemid 30199258)
101. Petrin J, Rozman B, Dolenc P, Logar D, Bozic B, Vizjak A, Ferluga D, Jezersek P. The dissociation of arterial hypertension and lupus glomerulonephritis in systemic lupus erythematosus. Blood Press 2: 108-112, 1993. (Pubitemid 23283625)
102. Piper MK, Raza K, Nuttall SL, Stevens R, Toescu V, Heaton S, Gardner-Medwin J, Hiller L, Martin U, Townend J, Bacon PA, Gordon C. Impaired endothelial function in systemic lupus erythematosus. Lupus 16: 84-88, 2007. (Pubitemid 46347929)
103. A receptor-mediated responses to endothelin- 1 and big endothelin-1 in the rat kidney. Br J Pharmacol 111: 729-732, 1994.
104. Prkacin I, Novak B, Sertic J, Mrzljak A. Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus. Acta Med Croatica 55: 73-76, 2001.
105. Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter CM, Pfab T, Bauer C, Kraemer-Guth A, Galle J, Yanagisawa M, Hocher B. Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens 23: 979-985, 2005. (Pubitemid 40637916)
106. Rahman P, Aguero S, Gladman DD, Hallett D, Urowitz MB. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 9: 672-675, 2000. (Pubitemid 32011792)
107. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 45: 9-14, 2005. (Pubitemid 40066405)
108. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242-251, 2007. (Pubitemid 47067483)
109. Reilly CM, Gilkeson GS. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 25: 143-153, 2002. (Pubitemid 34264100)
110. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 13: 290-297, 2004.
111. Rudofsky UH, Dilwith RL, Roths JB, Lawrence DA, Kelley VE, Magro AM. Differences in the occurrence of hypertension among (NZB x NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol 116: 107-114, 1984. (Pubitemid 14087098)
112. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR-γ ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4: 465-477, 2004.
113. Ryan MJ, McLemore GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 292: R736-R742, 2007.
114. Ryan MJ, McLemore, GR Jr, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48: 988-993, 2006.
115. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 144: 927-937, 1994. (Pubitemid 24984180)
116. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 33: 1545-1552, 2006. (Pubitemid 44168825)
117. Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 47: 1168-1175, 1995.
118. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37: 1075-1082, 2001. (Pubitemid 32304007)
119. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 49: 304-310, 2007. (Pubitemid 46150768)
120. Sheikh IA, Kaplan AP. Assessment of kininases in rheumatic diseases and the effect of therapeutic agents. Arthritis Rheum 30: 138-145, 1987.
121. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. In press.
122. Smolen JS. Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res 4 Suppl 3: S25-S30, 2002.
123. Song YW, Kim HA, Baek HJ, Lee EB, Chung ES, Hong KM. Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus. Int J Immunopharmacol 20: 669-677, 1998. (Pubitemid 28535149)
124. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R. The deletion/insertion polymorphism of the angiotensin-converting enzyme gene and cardiovascularrenal risk. J Hypertens 15: 1579-1592, 1997. (Pubitemid 28029652)
125. Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the antioestrogen tamoxifen on systemic lupus erythematosus of (NZB x NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62: 341-346, 2003. (Pubitemid 36363441)
126. Suryaprabha P, Das UN, Ramesh G, Kumar KV, Kumar GS. Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids 43: 251-255, 1991.
127. Suwannaroj S, Lagoo A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 10: 258-265, 2001. (Pubitemid 32332147)
128. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 40: 684-688, 2002.
129. Tesar V, Jirsa M Jr, Zima T, Kalousova M, Bartunkova J, Stejskalova A, Dostal C, Zabka J. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monit 8: BR24-BR29, 2002. (Pubitemid 34136311)
130. Tesar V, Masek Z, Rychlik I, Merta M, Bartunkova J, Stejskalova A, Zabka J, Janatkova I, Fucikova T, Dostal C, Becvar R. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 13: 1662-1667, 1998. (Pubitemid 28306791)
131. Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention. Hong Kong Med J 8: 26-32, 2002.
132. Thomas TJ, Messner RP. Difluoromethylornithine therapy of female NZB/W mice. J Rheumatol 18: 215-222, 1991.
133. Trebeden-Negre H, Weill B, Fournier C, Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol 33: 1603-1612, 2003. (Pubitemid 36790421)
134. Tso TK, Huang HY, Chang CK, Liao YJ, Huang WN. Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol 23: 416-420, 2004.
135. Turi S, Nemeth I, Torkos A, Saghy L, Varga I, Matkovics B, Nagy J. Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med 22: 161-168, 1997.
136. Uhm WS, Lee HS, Chung YH, Kim TH, Bae SC, Joo KB, Kim TY, Yoo DH. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus 11: 227-233, 2002.
137. Urowitz MB, Gladman DD, bu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24: 1061-1065, 1997. (Pubitemid 27250109)
138. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2: 582-593, 2006. (Pubitemid 44465680)
139. Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M, Badimon L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens 19: 457-462, 2005. (Pubitemid 40767181)
140. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9: 414-417, 2001. (Pubitemid 33603868)
141. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 152: 2082-2088, 1992.
142. Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka JD, Sysa-Jedrzejowska A. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediators Inflamm 8: 93-100, 1999. (Pubitemid 29243183)
143. Weimann BJ, Hermann D. Inhibition of autoimmune deterioration in MRL/lpr mice by vitamin E. Int J Vitam Nutr Res 69: 255-261, 1999. (Pubitemid 29351047)
144. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913-R935, 2005.
145. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15: 2792-2800, 2004.
146. Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol 52: 393-400, 2000.
147. Xiong Z, Huang H, Li J, Wang H. [PPAR-γ expression in the kidney of actively proliferating glomerulonephritis]. Beijing Da Xue Xue Bao 35: 499-502, 2003.
148. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54: 361-365, 1995.